Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression

Summary

This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to evaluate if high-dose Octagam 10% therapy can stabilize or improve clinical status in patients with severe Coronavirus disease

Timeline

Start

2020-06-01

Primary completion

2022-02-01

Completion

2022-02-01

Drugs

Indications